Cargando…

Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3–6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial

AIMS/HYPOTHESIS: The aim of this study was to compare the pharmacokinetics of two different concentrations of insulin aspart (B28Asp human insulin) in children aged 3–6 years with type 1 diabetes. METHODS: Young children with type 1 diabetes underwent an open-label, randomised, two-period crossover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Yue, Elleri, Daniela, Allen, Janet M., Tauschmann, Martin, Wilinska, Malgorzata E., Dunger, David B., Hovorka, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351431/ https://www.ncbi.nlm.nih.gov/pubmed/25537835 http://dx.doi.org/10.1007/s00125-014-3483-6

Ejemplares similares

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength
por: Elleri, Daniela, et al.
Publicado: (2014)

Closed-loop insulin delivery for treatment of type 1 diabetes
por: Elleri, Daniela, et al.
Publicado: (2011)

Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes
por: Murphy, Helen R., et al.
Publicado: (2011)

Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery
por: Ruan, Yue, et al.
Publicado: (2015)

Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial
por: Tauschmann, Martin, et al.
Publicado: (2016)

Pharmacokinetics of Insulin Aspart in Pump-Treated Subjects With Type 1 Diabetes: Reproducibility and Effect of Age, Weight, and Duration of Diabetes
por: Haidar, Ahmad, et al.
Publicado: (2013)

Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes
por: Tauschmann, Martin, et al.
Publicado: (2015)

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
por: Tauschmann, Martin, et al.
Publicado: (2018)

Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes: Randomized clinical trial
por: Elleri, Daniela, et al.
Publicado: (2013)

Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies
por: Hovorka, Roman, et al.
Publicado: (2011)

Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes: A randomized crossover case series
por: Murphy, Helen R., et al.
Publicado: (2011)

Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial
por: Hovorka, Roman, et al.
Publicado: (2014)

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol
por: Boughton, Charlotte, et al.
Publicado: (2020)

Faster insulin action is associated with improved glycaemic outcomes during closed‐loop insulin delivery and sensor‐augmented pump therapy in adults with type 1 diabetes
por: Ruan, Yue, et al.
Publicado: (2017)

Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study
por: Lawton, Julia, et al.
Publicado: (2019)

Hypoglycaemia incidence and recovery during home use of hybrid closed‐loop insulin delivery in adults with type 1 diabetes
por: Ruan, Yue, et al.
Publicado: (2018)

Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study
por: Bally, Lia, et al.
Publicado: (2017)

New closed-loop insulin systems
por: Boughton, Charlotte K., et al.
Publicado: (2021)

Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery
por: Krutkyte, Gabija, et al.
Publicado: (2023)

Closed‐loop insulin delivery in end‐of‐life care: a case report
por: Boughton, C. K., et al.
Publicado: (2019)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

Correction to: New closed-loop insulin systems
por: Boughton, Charlotte K., et al.
Publicado: (2021)

Mixed‐meal tolerance test to assess residual beta‐cell secretion: Beyond the area‐under‐curve of plasma C‐peptide concentration
por: Ruan, Yue, et al.
Publicado: (2019)

Feasibility of automated insulin delivery guided by continuous glucose monitoring in preterm infants
por: Beardsall, Kathryn, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart
por: Goudie, Robert J. B., et al.
Publicado: (2015)

Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial
por: Daly, Aideen B., et al.
Publicado: (2023)

Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial
por: Schierloh, Ulrike, et al.
Publicado: (2019)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents
por: Barnard, Katharine D, et al.
Publicado: (2014)

Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes
por: Tauschmann, Martin, et al.
Publicado: (2017)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
por: Kumar, Ajay, et al.
Publicado: (2016)

Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions
por: Thabit, Hood, et al.
Publicado: (2015)

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
por: Billings, LK, et al.
Publicado: (2019)

Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial
por: Boughton, Charlotte K, et al.
Publicado: (2019)

Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial
por: Boughton, Charlotte K., et al.
Publicado: (2021)

Day and Night Closed-Loop Control in Adults With Type 1 Diabetes: A comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management
por: Luijf, Yoeri M., et al.
Publicado: (2013)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

SAT167 Risk Of Life Threatening Hypoglycemia When Using U-100 Insulin Syringes To Administer R U-500 Insulin
por: Rizwan, Tehlil, et al.
Publicado: (2023)

Impact of the CamAPS FX hybrid closed‐loop insulin delivery system on sleep traits in older adults with type 1 diabetes
por: Thabit, Hood, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4frnqembrjij62ieb450cp5s57